Maxim Group Starts Moleculin Biotech (MBRX) at Buy
Tweet Send to a Friend
Maxim Group analyst Jason McCarthy initiates coverage on Moleculin Biotech (NASDAQ: MBRX) with a Buy rating and a price target ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE